Nektar Therapeutics (MEX:NKTR) Stock Based Compensation: MXN222 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NKTR Nektar Therapeutics MEX:NKTR
47 GF Score
Price MXN1,584.15
GF Value MXN134.27
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Stock Based Compensation?

Nektar Therapeutics MEX:NKTR 47 Stock Based Compensation is MXN222 Mil as of Mar. 2026. GuruFocus rates MEX:NKTR with a GF Score™ of 47/100 and a GF Value™ of MXN134.27. The stock has 5 warning signs investors should review.

Nektar Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was MXN61 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was MXN222 Mil.

Nektar Therapeutics Stock Based Compensation Related Terms

Nektar Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Stock Based Compensation Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,942.14 1,117.51 566.74 450.73 227.75

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.75 65.64 56.35 39.49 60.50
MEX:NKTR
47GF Score
Nektar Therapeutics MEX:NKTR
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN222 Mil.

What does a Stock Based Compensation of MXN222 Mil mean?
Nektar Therapeutics (MEX:NKTR) has a Stock Based Compensation of MXN222 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Stock Based Compensation too high?
Nektar Therapeutics' current Stock Based Compensation is MXN222 Mil. Overall, Nektar Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Stock Based Compensation compare to OCUL and PVLA?
Nektar Therapeutics' Stock Based Compensation of MXN222 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Nektar Therapeutics and its competitors. Nektar Therapeutics's current Stock Based Compensation is MXN222 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Nektar Therapeutics (MEX:NKTR) has a current Stock Based Compensation of MXN222 Mil. The stock's GF Value™ is MXN134.27, compared to a current price of MXN1,584.15 — trading 1079.8% above its estimated fair value. The current Stock Based Compensation is MXN222 Mil. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Nektar Therapeutics (MEX:NKTR), the current Stock Based Compensation is MXN222 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (MEX:NKTR) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of MXN1,584.15 is trading 1079.8% above its estimated GF Value™ of MXN134.27.

Key valuation signals for MEX:NKTR:

  • Stock Based Compensation: MXN222 Mil
  • GF Value™: MXN134.27 vs. price of MXN1,584.15 (1079.8% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the MEX:NKTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score

Get the complete analysis for MEX:NKTR

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,584.15
Price
MXN134.27
GF Value